Participation in 'The 113th Congress of Japan Society of Aesthetic Surgery,' May 2025
Yoshiyuki Aikawa, CEO of SBC Medical Group Holdings Incorporated
The Japan Society of Aesthetic Surgery (JSAS), one of Japan's leading professional societies in the field of aesthetic medicine, brings together doctors dedicated to shaping the future of the industry. 'The 113th Congress of Japan Society of Aesthetic Surgery' was held over three days from Wednesday, May 28 to Friday, May 30, 2025, at The Okura Tokyo. Under the theme 'TO BE THE BEST -The Journey of Knowledge Never Ends-,' the congress was chaired in part by Dr. Ayaka Nishikawa, Director of Dermatology Department of Shonan Beauty Group, who served as Vice Chair of the event. The congress provided a valuable platform for in-depth discussions on international trends and future developments in aesthetic medicine, fostering both academic and clinical insights and promoting global collaboration among experts in the field.
Dr. Ayaka Nishikawa, Director of Dermatology Department of Shonan Beauty Group, served as Vice Chair of this Congress
At this congress, a total of 22 representatives from SBC Medical presented their research findings, including Yoshiyuki Aikawa, CEO of SBC Medical, Dr. Daisuke Nakamura, Chief Medical Director of Shonan Beauty Group, Dr. Kazuhiro Igawa, Representative Assistant of Shonan Beauty Group and Dr. Ayaka Nishikawa, who also served as Vice Chair of the congress. Each speaker shared insights cultivated through daily clinical practice and research in their respective fields of expertise. The event also featured lively discussions on global trends and future developments in aesthetic medicine, providing a valuable opportunity to deepen academic and clinical knowledge and to foster international collaboration.
Dr. Daisuke Nakamura, Chief Medical Director of Shonan Beauty Group
Dr. Kazuhiro Igawa, Representative Assistant of Shonan Beauty Group
In the rapidly evolving field of aesthetic medicine, the importance of both acquiring and sharing specialized knowledge continues to grow. As technological advancements drive increasingly diverse customer needs, it is essential not only to adopt cutting-edge technologies, but also to maintain a broad and multifaceted perspective. SBC Medical remains committed to contributing to the advancement of the aesthetic medicine industry by actively engaging with academic societies and research institutions, sharing our innovative initiatives, and incorporating the latest global knowledge and technologies into our practice.
The 113th Congress of Japan Society of Aesthetic Surgery
Venue：The Okura Tokyo
Dates：Wednesday, May 28 – Friday, May 30, 2025
Official website： https://square.umin.ac.jp/jsas113/index.html
Presentation Topics
Chair / Speaker Job Title Title
Yoshiyuki Aikawa CEO, SBC Medical Group Holdings 【Special Program/Speaker】 Practical Strategies for Cosmetic Medical Business Management and Marketing
【Special Lecture/Chair】The future of cosmetic medicine and AI
Daisuke Nakamura Chief Medical Director of Shonan Beauty Group,
Chief of Breast Augmentation at SBC 【Symposium/Speaker】Creating an attractive bust line - Fat injection breast augmentation and breast implant augmentation
Kazuhiro Igawa Representative Assistant and Technical Advisor,
Shonan Beauty Group 【Symposium/Speaker】Rhinoplasty with an awareness of harmony by considering facial parts as fonts
Ayaka Nishikawa Director of Dermatology
Department of Shonan Beauty Group 【Luncheon Seminar/Chair/Speaker】The Potential of Microneedle RF：Indications and Practical Combination Treatments in Skin Management
【Invited Lecture/Chair】Unique Treatments and Techniques with injectable Agents A 35 Year Evolution
【Symposium/Speaker】Challenges in Skin Tightening Devices: Insights from Single-Device Treatments with 6.78MHz Monopolar RF
【Sponsored Seminar/Chair】'The WHY'? -Why do we do what we do as an aesthetics injector?
【Presidential Special Program/Speaker】Evaluating the Impact of Different Approaches in Aesthetic Dermatology: A Post-Treatment Study in Identical Twins
【Sponsored Seminar/Speaker】Fine fiber sheet for application after pico-second laser treatment
Jiro Kataoka Area Medical Director and Anti-Aging Expert Doctor 【Panel Discussion/Speaker】Deep Plane Facelift for Japanese (Asians) ~My Experience and Ideas~
【Video Lecture/Chair】Fundamentals and applications of Facelift Surgery: Strategies for Addressing Age-Related Changes
Shoko Takahashi Top expert doctor in rejuvenation 【Panel Discussion/Speaker】Patient education and combination treatment to maximize patient satisfaction with thread lifting
Hiroaki Takizawa Area Doctor and Director of Jiyugaoka Clinic 【Symposium/Speaker】Revision after double eyelid surgery with sub-brow blepharoplasty
Eiko Tanaka Director of Takatsuki Hospital 【Symposium/Chair/Speaker】Innovative Approaches to Improve Labia Majora Laxity: Minimizing Scars in Reduction Surgery
Atsushi Hayashi Chief Technical Director 【Panel Discussion/Speaker】Incidence of Post-inflammatory Hyperpigmentation with Picosecond Laser in Patients with Melasma
Kanako Misono Slimming Expert Doctor 【Luncheon Seminar/Speaker】Cutting edge of Cryolipolysis: Maximize patient satisfaction with Coolsculpting
Soichiro Morikawa Anti-aging treatment expert doctor 【Luncheon Seminar/Speaker】Polynucleotide products and Hyaluronic Acid Filler
Poster Presentations
Speaker Job Title Title
Hiroshi Ohji ー Usefulness of preoperative ultrasound examination in submandibular liposuction.
Ayano Okuda Expert doctor in gynecological plastic surgery Diversifying Intimate Area Treatments ~Changes and Current Status of Pubic Hair Removal and Female Genital plastic surgery at Our Clinic~
Go Kanazawa Director of Hiroshima Clinic and Area Doctor for Hiroshima Area Lessons learned from the experience of removing limps formed by fat injection into the lower eyelid
Kaito Kuzushima Ginza Clinic Director
Top Expert Doctor in Liposuction Asian Buttocks Contouring：witout fat injection 【Evaluated with 3D Vectra】
Aiko Ssasaki Kawagoe Area Area
Doctor and Director of Kawagoe Clinic Comparison of eyelid functions before and after completely transconjunctival embedding double eyelid blepharoplasty
Yuka Takeda Director of the Esaka Institute The usefulness of next generation needle Nanosoft Microneedles
Lifting Effects and Technical Innovations in Full-Face Autologous Fat Grafting
Ryuji Tanaka Hokkaido/Tohoku Area General Manager Approach to the Management of Lower Eyelid Hollowness with Skin Laxity
Mei Nakayama ー Bilateral symmetrical enlargement within a few months after upper arm liposuction : case report
Ayaka Nishikawa Director of Dermatology
Department of Shonan Beauty Group Fine fiber sheet for application after pico-second laser treatment
Yu Hirata Director of Okayama Clinic and Area Doctor for Okayama Area Study on the direction of fat repositioning in transconjunctival blepharoplasty.
Takashi Yamamoto Director of Nagoya Institute Examination of the effects, satisfaction, and risks of orbital fat removal combined with the buried double method
Akihiro Yoshida ー Tips to improve the success rate of transconjunctival double eyelid blepharoplasty suture removal
About SBC Medical
SBC Medical, headquartered in Irvine, California and Tokyo, Japan, owns and provides management services and products to cosmetic treatment centers. The Company is primarily focused on providing comprehensive management services to franchisee clinics, including but not limited to advertising and marketing needs across various platforms (such as social media networks), staff management (such as recruitment and training), booking reservations for franchisee clinic customers, assistance with franchisee employee housing rentals and facility rentals, construction and design of franchisee clinics, medical equipment and medical consumables procurement (resale), the provision of cosmetic products to franchisee clinics for resale to clinic customers, licensure of the use of patent-pending and non-patented medical technologies, trademark and brand use, IT software solutions (including but not limited to remote medical consultations), management of the franchisee clinic's customer rewards program (customer loyalty point program), and payment tools for the franchisee clinics. For more information, visit https://sbc-holdings.com/
Contacts
In Asia:
SBC Medical Group Holdings Incorporated
Hikaru Fukui / Head of Investor Relations
E-mail: ir@sbc-holdings.com
In the US:
ICR LLC
Bill Zima / Managing Partner
Email: bill.zima@icrinc.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
40 minutes ago
- Globe and Mail
Imagen Network Uses Grok Intelligence to Improve Real Time Personalization in Social Apps
Integration enhances adaptive feeds and user-specific content delivery in decentralized environments. Singapore, Singapore--(Newsfile Corp. - August 4, 2025) - Imagen Network (IMAGE), the decentralized AI social platform, has integrated Grok intelligence to enhance real-time personalization in its social applications. This strategic update brings smarter content discovery, adaptive curation, and seamless peer-to-peer interaction to Web3 users. Enhancing decentralized social experiences with smarter, adaptive AI tools. To view an enhanced version of this graphic, please visit: The integration enables Imagen to process behavioral data and contextual signals to deliver highly relevant and personalized feeds without compromising privacy. Communities can curate intelligently, while creators see their content reach audiences most likely to engage. Grok's intelligent inference strengthens Imagen's modular social nodes, ensuring personalization scales with network growth. The result is an experience where every interaction feels unique, intuitive, and responsive to the individual user's digital journey. By fusing advanced AI with blockchain architecture, Imagen Network continues to lead the evolution of decentralized social ecosystems, offering a smarter and user-centric approach to Web3 connectivity. About Imagen Network Imagen Network is a decentralized social platform that blends AI content generation with blockchain infrastructure to give users creative control and data ownership. Through tools like adaptive filters and tokenized engagement, Imagen fosters a new paradigm of secure, expressive, and community-driven networking.
Japan Forward
5 hours ago
- Japan Forward
Do Not Open Japan-US Trade Deal to Distorted Interpretation
このページを 日本語 で読む A trade deal was concluded by the Shigeru Ishiba administration and the Donald Trump administration. But, were the provisions of the agreement actually finalized? It is difficult to dispel doubts on that score. There are stark differences in how the Japanese and US sides explain provisions on new investment in the United States. This is a cause for concern in the actual implementation of the agreement. One of the main pillars of the Japan-US agreement sets reciprocal tariffs and auto tariffs the US imposes on Japanese imports at 15%. However, no written agreement has been drawn up. Isn't that the cause of the differences in perception between the two sides? Prime Minister Shigeru Ishiba should have spoken directly with President Trump immediately after the agreement was reached to share his views. His failure to do so has created a major problem. If things continue as they are, it is possible that the US side will try to force its own interpretation on Japan. If that were to happen, Japan's national interest might well suffer damage. The Prime Minister and Minister for Economic Revitalization Ryosei Akazawa should clarify the reasons for these differing perceptions during the extraordinary Diet session that convened on August 1. They have a duty to explain to the satisfaction of the Japanese people that the agreement will be appropriately implemented. US President Donald Trump speaks at the White House on July 31 (©Reuters via Kyodo) Regarding Japanese investment in the United States, Trump posted on social media that Japan will invest $550 billion USD (approximately ¥80 trillion JPY) in the United States. Furthermore, he said, the US will receive 90% of the profits. In response, the Japan side has explained that the $550 billion in question is actually the upper limit for investments, loans, and loan guarantees. Of this, the "90%" of the profits the US would stand to make from the deal are from investment projects. That amounts to just 1% to 2% of the $550 billion, according to Akazawa. As for the issue of rice, the US side claims that Japan's imports of American rice will increase by 75%. However, Japan has not provided any specific details. Won't this really amount to sacrificing Japan's agricultural sector? US Treasury Secretary Scott Bessent has also declared that he intends to review Japan's compliance with the agreement quarterly. He has further threatened that tariffs will be raised to 25% if Trump is not satisfied. That would provide leeway for Trump to unilaterally scrap the agreement. The lack of a joint document sharing a mutual understanding of what the agreement entails has left a legacy of problems. The Japanese side prioritized an early conclusion to the talks. That allowed the delay of the time-consuming task of hammering out a written agreement. Their excuse was to avoid a situation where an agreement could not be reached by the Trump-imposed deadline of August 1. On that date, Trump's reciprocal tariffs on Japan were scheduled to rise to 25%. Even if that is true, it will end up counterproductive if the agreement comes to be distorted by the US interpretation. Above all, the Ishiba government should urge the Trump administration to quickly align their respective views. We should realize that, unless both sides share a mutual understanding, economic uncertainty from Trump's tariffs will not dissipate. Author: Editorial Board, The Sankei Shimbun このページを 日本語 で読む
Globe and Mail
2 days ago
- Globe and Mail
Merging AI and Quantum Computing: Here's the Stock to Watch
Key Points With its cutting-edge GPUs, Nvidia is a formidable force in the AI industry. Collaborating with quantum computer developers and Japanese researchers, Nvidia is applying its AI capabilities to advance quantum computing. While Nvidia stock seems pricey, it's a no-brainer option for investors seeking both AI and quantum computing exposure. 10 stocks we like better than Nvidia › Bread is great. Meat -- or the vegetarian filling of your choice -- is great, too. But it was the Earl of Sandwich who married the two in the 1700s to create the sandwich as we know it. The race to integrate artificial intelligence (AI) and quantum computing doesn't require the ingenuity of an English nobleman. Today, tech leaders are racing to incorporate the two technologies to revolutionize computing abilities. While Nvidia (NASDAQ: NVDA) is often recognized as an AI industry stalwart, the company is also helping to advance quantum computing, making it a smart choice for those interested in gaining simultaneous exposure to the two burgeoning industries. The company for all AI seasons It's hard to overestimate Nvidia's position as an AI leader, since it has a hand in the varying niches of the AI field. Nvidia AI Foundry, for example, offers customers an end-to-end platform and service for constructing custom generative AI models, including large language models and AI chatbots. Additionally, Nvidia AI Enterprise provides a cloud-native suite of software tools, libraries, and frameworks. Nvidia's graphic processing units (GPUs) provide the backbone for its AI proficiency. The company's latest GPU architecture, Nvidia Blackwell, is in high demand from data centers, where AI computing occurs. Earlier in July, hyperscaler CoreWeave announced that it was "the first cloud provider to deliver this groundbreaking GPU architecture for AI, graphics, and high-performance computing workloads." Like CoreWeave, hyperscaler peer Nebius is rolling out availability to Blackwell architecture to customers, and the company is, unsurprisingly, extremely enthusiastic. In June, Nebius announced that the Blackwell architecture was now available to customers in Europe. With respect to the United States, Nebius is developing a data center in New Jersey that the company plans on singularly dedicating to Nvidia Blackwell-architecture GPUs. Making the quantum leap Unlike companies such as IonQ and Rigetti Computing, which are building actual quantum computers, Nvidia is taking a different -- though necessary -- tack to advancing the nascent field. For one, Nvidia is building a research center in Boston that will integrate its Nvidia GB200 Grace Blackwell superchip (providing advanced AI computing) with quantum computing hardware. The result will be accelerated quantum supercomputing that Nvidia says "will help solve quantum computing's most challenging problems, ranging from qubit noise to transforming experimental quantum processors into practical devices." A qubit is the basic unit of information in quantum computing. Providing 2,020 of its H100 GPUs interconnected by its Quantum-2 InfiniBand networking platform to Japan's National Institute of Advanced Industrial Science and Technology (AIST), Nvidia is also playing a pivotal role in facilitating progress at the ABC1-Q, the world's largest research supercomputer dedicated to quantum computing. In addition, the system is integrated with Nvidia CUDA-Q, an open-source hybrid computing platform that assists hardware and software to conduct enormous quantum computing applications. Speaking to the collaboration between Nvidia and the AIST, Tim Costa, Nvidia's senior director of computer-aided engineering, quantum and CUDA-X, was quoted as saying: Seamlessly coupling quantum hardware with AI supercomputing will accelerate realizing the promise of quantum computing for all. Nvidia's collaboration with AIST will catalyze progress in areas like quantum error correction and applications development -- crucial for building useful, accelerated quantum supercomputers. Is Nvidia a no-brainer buy today for AI and quantum computing exposure? There are several AI leaders and a handful of quantum computing pioneers, however, Nvidia is one of the very few companies developing technologies for both tech fields. This makes it an obvious consideration for those interested in a single investment that provides exposure to both corners of the tech industry. Taking a quick look at the stock's valuation, investors may conclude that shares are pricey now, trading at roughly 56 times trailing earnings. It's important to recognize, though, that Nvidia's position as a semiconductor and AI powerhouse has led to it commanding a higher valuation -- it's five-year average trailing P/E is 70. Therefore, investors shouldn't dismiss the stock as unattractively valued. And though there may be bumps in the road as these two fields mature, Nvidia is an excellent choice for investors looking to be in position to prosper from the growth of AI and quantum computing. Should you invest $1,000 in Nvidia right now? Before you buy stock in Nvidia, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Nvidia wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $625,254!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,090,257!* Now, it's worth noting Stock Advisor's total average return is 1,036% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025
